Invus Global Management, LLC
Invus Global Management, LLC's purchase track record
Invus Global Management, LLC has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/2/2026 | LXRX | $2.00M | +28.0% | +86.4% | +8.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Transaction History
| LXRX | ▲ Buy | Open Market | 1,538,462 | $2.0M | 2/2/2026 | View on chart |
| LXRX | ▲ Buy | Grant | 367,145 | $23.9M | 2/2/2026 | View on chart |
| LXRX | ▲ Buy | Grant | 18,553,846 | $24.1M | 2/2/2026 | View on chart |
| LXRX | ▲ Buy | Grant | 3,846,154 | $5.0M | 2/2/2026 | View on chart |
| SRRK | ▼ Sell | Other | 1,575,008 | $11.6M | 12/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis
Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis. Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.